Preconference Workshops
Monday, October 30, 2023
Workshop A
8:00 - 11:00am
Workshop B
12:00 - 3:00pm
Workshop C
3:30 - 6:30pm
Expanding the Reach of HER2 Therapeutics to New Patients through Rational & Efficient Exploration of Non-Breast Cancer Tumors
Success in treating breast cancer has led the field to explore new disease types that HER2+ has led to a massive growth in non-breast cancer HER2 trials. Over 44 trials in ADCs alone and 31 in bispecific antibodies there is more and more data flooding in. Many are asking what the biological evidence is for going after specific
cancers such as lung, gut, bladder, or oesophageal, and what are the key markers
of a HER2+ cancer type that makes it a good target.
Topics will include:
- A history of HER2+ non-breast tumors, recent clinical development, and the
current standard of care - Discussion of the core biological reasons why each of the non-breast tumors make good targets and how the mechanism of action may differ
- Assessment of potential risks, their pathophysiological features, and side effects going after alternate cancers
Haesong Park
Member of the Faculty of Medicine
Dana Farber Cancer Institute
Sam Cytryn
Principal Investigator
MSKCC
Utilizing Novel Imaging & Diagnostics Modalities to Optimize
Response Rates Through
Better Patient Selection
Current immunohistochemistry is a key rate-limiting factor when it comes to clinical
development and new tools need to be adopted to improve outcomes for patients,
as well as clinical readouts for new drugs in development. In this workshop we
will discuss the shortcomings of current technology in depth, uncovering the main
areas where novel tools could revolutionize HER2 therapeutic development. Topics
will include:
- How far does IHC take us, what are the limitations when it comes to diagnosing HER2-Low with IHC?
- What requirements would a novel diagnostic tool need to meet to surpass the quality of information offered by IHC?
- How many biopsies are required for IHC and what conditions need to be met for
additional biopsies to be taken? - Where is the best place to start with novel diagnostics? Possibilities include:
• Circulating HER2
• Identifying alternate non-HER2 biomarkers
• The core technology itself - Must a companion diagnostic be therapeutic-specific?
- Regulatory concerns around specificity and accuracy of diagnostics relative to
current diagnostic standards - Gain a better grounding in novel imaging technologies that are on the horizon for HER2 drug developers and gain a better understanding of their capabilities and challenges
Guido Würth
Global Head of Programs
Affibody
Haesong Park
Member of the Faculty of Medicine
Dana Farber Cancer Institute
Carl Barrett
(Former) Vice President - Translational Science and Oncology Institute of Management & Entrepreneurship Development
(Former) AstraZeneca
Reviewing Brain Metastasis on a Biological Level & Assessing Novel Therapeutics for Extending Survival in Advanced Disease
Targeting the later stages of the metastatic disease require novel treatment options. There has been minimal development in our biological understanding of HER2+ brain metastasis but clinical data of therapies new and old continues to flood in. Here we will take a deep look at these therapies, their benefits, risks, and
future development plans. Topics will include:
- HER2 targeted Tyrosine Kinase inhibitors and their role in a patient’s treatment
schedule - Exploration of the HER2 brain metastasis drug landscape
- Side effects of current therapies and their management requirement
Guido Würth
Global Head of Programs
Affibody
Carl Barrett
(Former) Vice President - Translational Science and Oncology Institute of Management & Entrepreneurship Development
(Former) AstraZeneca
To see the full 3-day agenda download the full Event Guide. Which includes:
- 20+ Expert Speaker Faculty
- Interactive workshops
- Full access to the 3-day conference agenda
- & more
